跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
HSA
/
Daxotel Concentrate for Solution for Infusion 20mg/ml
Approved
THERAPEUTIC
Daxotel Concentrate for Solution for Infusion 20mg/ml
Fresenius Kabi Oncology Limited
🇸🇬 Health Sciences Authority
Approval Date
Oct 26, 2016
Approval ID
55b57df55b9330e3
Company
Fresenius Kabi Oncology Limited
Type
Therapeutic
Approval Details
Approval Id
55b57df55b9330e3
Drug Name
Daxotel Concentrate for Solution for Infusion 20mg/ml
Product Name
Daxotel Concentrate for Solution for Infusion 20mg/ml
Approval Number
SIN15109P
Approval Date
2016-10-26
Registrant
FRESENIUS KABI (SINGAPORE) PTE LTD
Licence Holder
FRESENIUS KABI (SINGAPORE) PTE LTD
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
INJECTION, SOLUTION, CONCENTRATE
Route Of Administration
INTRAVENOUS
Atc Code
L01CD02
Atc Item Name
docetaxel
Pharma Manufacturer Name
FRESENIUS KABI (SINGAPORE) PTE LTD
Company Detail Path
/organization/fresenius-kabi-singapore-pte-ltd
Active Ingredients
Docetaxel Anhydrous
20.0mg/ml
DOCETAXEL ANHYDROUS
20 MG/ML
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Oct 26, 2016
Approval ID
55b57df55b9330e3
Type
Therapeutic
Back to HSA Approvals
Daxotel Concentrate for Solution for Infusion 20mg/ml - HSA Drug Approval Details
